SilverCloud Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital mental health platform delivering evidence-based CBT programs, Dublin Ireland, acquired by Amwell, serves 500+ health systems and payers globally.
About
SilverCloud Health is a Dublin, Ireland-based digital mental health platform founded in 2012 at Trinity College Dublin. The company specializes in delivering structured, evidence-based cognitive behavioral therapy (CBT) programs through an asynchronous digital format supported by a trained human reviewer. SilverCloud was acquired by Amwell in 2021, integrating its digital mental health programs into Amwell's broader virtual care platform serving health systems, health plans, and employers.\n\nThe platform offers more than 20 condition-specific programs covering depression, anxiety, insomnia, chronic pain, diabetes, and workplace stress, among others. Each program is built on clinically validated CBT frameworks and follows a structured curriculum over six to eight weeks. Users work through modules independently and receive feedback and encouragement from a trained human supporter, a model known as supported self-management that has shown strong outcomes in peer-reviewed research.\n\nSilverCloud serves more than 500 health systems, insurers, and employers across the United Kingdom, Ireland, and the United States. Its clinical credibility is underpinned by a robust evidence base of over 90 published research studies, making it one of the most rigorously evaluated digital mental health interventions available. Following the Amwell acquisition, SilverCloud has expanded its reach through Amwell's existing hospital and health plan relationships.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.